ddn Online Cancer Top 5
FEBRUARY 2011


Here's a look at some of the most popular stories from our Cancer Special Report in the last news cycle:
 
The ABCs of ADCs
Seattle Genetics Inc. officials soon may be filling out a pretty sizable deposit slip in the form of an $8 million fee from Pfizer Inc. for rights to use its cancer-fighting antibody-drug conjugate technology.

A solid foundation for personalized medicine
Foundation Medicine Inc., a personalized cancer medicine company that aims to bring comprehensive cancer genome analysis to routine clinical care, will collaborate with Novartis to develop, enhance and optimize Foundation's cancer genome panel test for Novartis' needs.

It's in the genes
EpiTherapeutics and Abbott got in the holiday spirit by announcing a three-year collaboration agreement in late December to develop new anti-cancer drugs by making small-molecule inhibitors against carefully chosen epigenetic oncology targets.

Getting its feet wet
Signaling a paradigm shift in the organization, Beckman Coulter Inc. recently announced the company's foray into the companion diagnostics market via an agreement with French biopharmaceutical firm Transgene to develop a companion test to be used alongside clinical trials of Transgene's Phase III-stage anticancer candidate, TG4010.

Metamark dives into cancer biomarkers
A multiyear licensing agreement was signed in late December by Metamark Genetics Inc., a privately held oncology-focused molecular diagnostics company, and HistoRx Inc., a diagnostics company developing tissue-based diagnostic solutions to advance individualized patient care.
©2011 Old River Publications LLC. All Rights Reserved.
Web site designed and managed by Offenberger & White, Inc..